QNCX Quince Therapeutics, Inc.
$29.55▲ +2.04%
Healthcare
Other
After hours
$29.55▲ +0.00%
Sep 11, 7:30 PM ET
Volume 11.3K
Avg Volume (10D) 18.5K
Key Metrics & Fundamentals
Market Cap
$30.05M
P/E Ratio
–
Div Yield
–%
52W Range
15.10 - 910.00
% vs 50 MA
13.37%
% vs 200 MA
-82.42%
RSI-14
48.7
MACD Histogram
-0.8100
Beta (1Y vs SPY)
2.03
Free Cash Flow
-$18.89M
Gross Rev
$0
Gross Profit
$0
EBITDA
$32.02M
COGS
–
Operating Exp
$22.09M
Operating Income
-$22.09M
EBIT
-$22.09M
Pretax Income
-$75.41M
Net Income
-$75.49M
EPS (Diluted)
-12.31
Price & Volume History
Loading chart…
Recent News
Quince Therapeutics to Participate in September 2026 Investor Conferences
GlobeNewswire · Sep 3, 2026 12:00 PM
Craig-Hallum Initiates Quince Therapeutics at Buy With $68 Price Target
MT Newswires · Aug 21, 2026 10:23 AM
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
GlobeNewswire · Aug 14, 2026 12:00 PM
As Acasti Pharma Advances FDA Orphan-Designated GTX-102 Oral Mucosal Spray, New Report Maps 7MM Ataxia-Telangiectasia Treatment Landscape
GlobeNewswire · Aug 14, 2026 8:05 AM
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
GlobeNewswire · Jun 30, 2026 12:00 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See QNCX's money flow as a full page
Social Sentiment
Avg -0.60 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.